資料載入中.....
|
請使用永久網址來引用或連結此文件:
https://ir.cnu.edu.tw/handle/310902800/31686
|
| 標題: | High Expression of Aldolase B Confers a Poor Prognosis for Rectal Cancer Patients Receiving Neoadjuvant Chemoradiotherapy |
| 作者: | Tian, Yu-Feng
Hsieh, Pei-Ling
Lin, Ching-Yih
Sun, Ding-Ping
Sheu, Ming-Jen
Yang, Ching-Chieh
Lin, Li-Ching
He, Hong-Lin
Solorzano, Julia
Li, Chien-Feng
Chang, I-Wei |
| 貢獻者: | Chi Mei Med Ctr, Dept Surg, Div Gen Surg
Chia Nan Univ Pharm & Sci, Dept Hlth & Nutr
Chi Mei Med Ctr, Dept Med Image
Chi Mei Med Ctr, Dept Internal Med, Div Gastroenterol & Hepatol
Southern Taiwan Univ Sci & Technol, Dept Leisure Recreat & Tourism Management
Chia Nan Univ Pharm & Sci, Dept Pharm
Chi Mei Med Ctr, Dept Radiat Oncol
I Shou Univ, E DA Hosp, Dept Pathol
I Shou Univ, Sch Med
Chi Mei Med Ctr, Dept Pathol
Natl Hlth Res Inst, Natl Inst Canc Res
Southern Taiwan Univ Sci & Technol, Dept Biotechnol
Kaohsiung Med Univ, Inst Clin Med |
| 關鍵字: | ALDOB
Aldolase B
CCRT
chemoradiotherapy
rectal cancer |
| 日期: | 2017 |
| 上傳時間: | 2018-11-30 15:52:52 (UTC+8) |
| 出版者: | Ivyspring Int Publ |
| 摘要: | Background: Colorectal cancer is the third most common cancer in both sex worldwide and it is also the fourth most common cause of cancer mortality. For rectal cancer, neoadjuvant concurrent chemoradiotherapy (CCRT) followed by radical proctectomy is gold standard treatment for patients with stage II/III rectal cancer. By data mining a documented database of rectal cancer transcriptome (GSE35452) from Gene Expression Omnibus, National Center of Biotechnology Information, we recognized that ALDOB was the most significantly up-regulated transcript among those related to glycolysis (GO: 0006096). Hence, we analyzed the clinicopathological correlation and prognostic effect of ALDOB protein (Aldolase B), which encoded by ALDOB gene. Methods: ALDOB immunostain was performed in 172 rectal adenocarcinomas treated with preoperative chemoradiotherapy followed by radical surgery, which were divided into high-and low-expression groups. Furthermore, statistical analyses were examined to correlate the relationship between ALDOB immunoreactivity and important clinical and pathological characteristics, as well as three survival indices: disease-specific survival (DSS), local recurrence-free survival (LRFS) and metastasis-free survival (MeFS). Results: ALDOB (Aldolase B) over-expression was significantly associated with pre-CCRT and post-CCRT tumor advancement, lymphovascular invasion, perineural invasion and poor response to CCRT (all P <= .023). In addition, ALDOB high expression was linked to adverse DSS, LRFS and MeFS in univariate analysis (P <= .0075) and also served as an independent prognosticator indicating dismal DSS and MeFS in multivariate analysis (hazard ratio (HR) = 3.462, 95% confidence interval (CI): 1.263-9.495; HR = 2.846, 95% CI: 1.190-6.808, respectively). Conclusion: ALDOB (Aldolase B) may play an imperative role in rectal cancer progression and responsiveness to neoadjuvant CCRT, and serve as a novel prognostic biomarker. Additional researches to clarify the molecular and biochemical pathways are essential for developing promising ALDOB-targeted therapies for patients with rectal cancers. |
| 關聯: | Journal of Cancer, v.8, n.7, pp.1197-1204 |
| 顯示於類別: | [藥學系(所)] 期刊論文
[保健營養系(所) ] 期刊論文
|
文件中的檔案:
| 檔案 |
描述 |
大小 | 格式 | 瀏覽次數 |
|---|
| index.html | | 0Kb | HTML | 1549 | 檢視/開啟 | | jca.18197.pdf | | 845Kb | Adobe PDF | 0 | 檢視/開啟 |
|
在CNU IR中所有的資料項目都受到原著作權保護.
|
